SELLAS Life Sciences has recently announced the completion of enrollment and initial positive data in the Phase 2a trial of SLS009 in patients with relapsed or refractory acute myeloid leukemia (r/r AML). The trial, which enrolled 30 patients who were relapsed or refractory to Venetoclax-based regimens ahead of schedule, has shown promising results thus far.
Additionally, the company has also received positive recommendations from the Independent Data Monitoring Committee following the completion of enrollment in the Phase 3 REGAL study. Based on the efficacy and safety data assessed, the IDMC has recommended the continuation of patient treatment and follow-up without any modifications.
In a recent update, SELLAS Life Sciences has announced positive topline data from the Phase 2a study of SLS009 in r/r AML and provided a steering committee update on the Phase 3 REGAL study. The Phase 3 REGAL study of SLS009 in AML has completed enrollment, with the steering committee guiding an imminent interim analysis. The IDMC is now scheduled to meet in late April to assess the data and potentially provide further recommendations.
These developments highlight the progress and potential of SELLAS Life Sciences in the field of AML treatment, showcasing positive results in both Phase 2a and Phase 3 trials. The company’s focus on innovative treatments and commitment to advancing the field of oncology are evident in the promising data and recommendations received thus far.
Comments